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Depletion of peroxisome proliferator-activated recep-
tor  (PPAR) accompanies myofibroblastic transdiffer-
entiation of hepatic stellate cells (HSC), the primary
cellular event underlying liver fibrogenesis. The treat-
ment of activated HSC in vitro or in vivo with synthetic
PPAR ligands suppresses the fibrogenic activity of
HSC. However, it is uncertain whether PPAR is indeed
a molecular target of this effect, because the ligands are
also known to have receptor-independent actions. To
test this question, the present study examined the ef-
fects of forced expression of PPAR via an adenoviral
vector on morphologic and biochemical features of cul-
ture-activated HSC. The vector-mediated expression of
PPAR itself is sufficient to reverse the morphology of
activated HSC to the quiescent phenotype with re-
tracted cytoplasm, prominent dendritic processes, re-
duced stress fibers, and accumulation of retinyl palmi-
tate. These effects are abrogated by concomitant
expression of a dominant negative mutant of PPAR
that prevents transactivation of but not binding to the
PPAR response element. PPAR expression also inhibits
the activation markers such as the expression of
-smooth muscle actin, type I collagen, and transform-
ing growth factor 1; DNA synthesis; and JunD binding
to the activator protein-1 (AP-1) site and AP-1 promoter
activity. Inhibited JunD activity by PPAR is not due to
reduced JunD expression or JNK activity or to a com-
petition for p300. But it is due to a JunD-PPAR inter-
action as demonstrated by co-immunoprecipitation and
glutathione S-transferase pull-down analysis. Further,
the use of deletion constructs reveals that the DNA bind-
ing region of PPAR is the JunD interaction domain. In
summary, our results demonstrate that the restoration
of PPAR reverses the activated HSC to the quiescent
phenotype and suppresses AP-1 activity via a physical
interaction between PPAR and JunD.
Hepatic stellate cells (HSC)1 are vitamin A-storing pericytes
in the subendothelial space of the liver. Upon injury to the
liver, HSC become transdifferentiated into myofibroblastic
cells to participate in wound healing (1). This transdifferentia-
tion is characterized by reduced vitamin A content, increased
cell proliferation and migration, enhanced matrix protein ex-
pression, and induced expression of -smooth muscle actin (1).
This response of HSC constitutes the normal, reparative ho-
meostatic response of the liver to injury. However, dysregula-
tion of HSC leads to excessive accumulation of extracellular
matrices, resulting in liver fibrosis and cirrhosis. No curative
medical treatments are available for cirrhosis except liver
transplantation, and a precise understanding of transdifferen-
tiation of HSC is the prerequisite for eventual identification of
“dysregulation” and future developments of specific therapeu-
tic modalities for the disease. To this end, much investigative
effort has been made to characterize transcriptional regulation
that underlies HSC transdifferentiation. Such examples in-
clude identification of Kruppel-like factor 6, a differentially
expressed zinc finger protein in activated HSC in vitro and in
vivo (2). This transcription factor binds to the GC box sites of
TGF1, TGF receptor type I and II (2), urokinase-type plas-
minogen activator (3), and 1(I) procollagen (2) and induces
transcription of these fibrogenic genes. The myofibroblastic
phenotype seen in activated HSC is best characterized by in-
duction of -smooth muscle actin that is mediated by c-Myb
binding to an E-box element in its promoter (4). The signifi-
cance of this mode of regulation is supported by the demonstra-
tion of prevention of the myofibroblastic phenotypic switch by
the treatment of HSC with antisense oligonucleotides for c-Myb
(4). Sustained NF-B activation confers activated HSC their
proliferative and antiapoptotic status that may be important in
progressive liver fibrogenesis (5). NF-B may also mediate
inflammatory responses by HSC via induction of chemokines
and adhesion molecules (6, 7). Increased activator protein-1
(AP-1) activity is essential for induction of matrix metallopro-
teinase (8), tissue inhibitor of matrix metalloproteinase-1, and
interleukin-6 (9) gene transcription in activated HSC, where
JunD is shown to play a pivotal role (9).
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A complexity in the understanding of HSC differentiation is
underscored by different cellular phenotypes that HSC are
shown to express. In addition to the myofibroblastic phenotype
exhibited by activated HSC, they also express MyoD, the myo-
genic transcription factor specific for skeletal muscle (9). Neu-
ronal markers such as GFAP (10), N-CAM (6), nestin (11), and
synaptophysin (12) are also expressed in HSC, suggesting the
neural phenotype and that N-CAM and nestin are induced in
activated HSC. Activated HSC express leptin (13), an adipo-
cyte-specific gene, raising an intriguing possibility that HSC
may also share the adipocytic phenotype. In fact, the quiescent
HSC is laden with lipids including triglycerides, cholesterol,
and phospholipids in addition to retinyl esters (14). In support
of this notion, peroxisome proliferator-activated receptor 
(PPAR), one of the key transcription factors for adipocyte
differentiation (15), is expressed in the quiescent HSC (16–18),
and its expression and activity decrease in HSC activation in
vitro (16, 17) and in vivo (16). Further, the treatment of culture-
activated HSC with the natural or synthetic ligands for PPAR
suppresses many functional parameters of the cell activation,
including cell proliferation (17), expression of collagen, TGF,
-smooth muscle actin, monocyte chemotactic protein-1 genes,
and chemotaxis (16, 18). More importantly, the treatment of
the animal models of liver fibrosis with the PPAR ligands
ameliorates not only induction of fibrosis but also progression
of preexisting fibrosis (17). Thus, these findings support the
hypothesis that the maintenance of the quiescent state of HSC
requires PPAR and depletion of this adipogenic transcription
factor underlies activation of HSC that can be circumvented by
the ligand treatment. However, the ligands for PPAR are also
known to have receptor-independent effects. Using the embry-
onic stem cells from PPAR null mice, neither macrophage
differentiation nor anti-inflammatory effects of synthetic
PPAR ligands are shown to be dependent on PPAR (19).
Indeed, the PPAR ligand 15-deoxyprostaglandin J2 sup-
presses NF-B activation by directly inhibiting IB kinase in a
PPAR-independent manner (20). Troglitazone also selectively
induces early growth response-1 gene independently of PPAR
(21). Mitogen-activated protein kinases such as c-Jun N-termi-
nal kinase (JNK), p38, and extracellular signal-regulated ki-
nase are activated by PPAR ligands such as 15-deoxyprostag-
landin J2 and ciglitazone in astrocytes and preadipocytes
through the mechanisms that are independent of PPAR but
involving reactive oxygen species (22). Therefore, it is yet to be
determined whether PPAR directly inhibits HSC activation.
In order to test this question, the present study was under-
taken to express PPAR via an adenoviral vector in culture-
activated HSC and to determine its effects on the cell activa-
tion. Our results demonstrate that the restoration of PPAR in
activated HSC induces a reversal of the morphological features
of HSC to the quiescent phenotype associated with inhibition of
the known activation markers such as induced -smooth mus-
cle actin, collagen, and TGF expression; enhanced DNA syn-
thesis; increased AP-1 binding; and promoter activity. Inhibi-
tion of AP-1 binding is due to PPAR-mediated interference of
JunD binding but not to suppression of JunD expression or
JNK activity. Further, our results demonstrate a direct inter-
action of the PPAR DNA binding domain with JunD that
appears to underlie inhibited JunD binding to the AP-1 site.
MATERIALS AND METHODS
HSC Isolation and Culture—HSC were isolated from normal male
Wister rats as previously described (23) by the Non-Parenchymal Liver
Cell Core of the USC-UCLA Research Center for Alcoholic Liver and
Pancreatic Diseases. The use of animals for this study was approved by
the Institutional Animal Care and Use Committee of the University of
Southern California (protocol 9823). In brief, the liver was sequentially
digested with Pronase and type IV collagenase to isolate nonparenchy-
mal cells. These cells were subsequently subjected to arabinogalactan
gradient ultracentrifugation to collect a pure fraction of HSC from the
interface between the medium and a density of 1.035. The purity of
isolated HSC was examined by phase-contrast microscopy, UV-excited
fluorescence microscopy, and the viability by trypan blue exclusion.
Isolated HSC from normal rats were cultured in a 100-mm plastic dish,
6- or 12-well plates with low glucose DMEM supplemented with 10%
fetal bovine serum (FBS), 100 mg/ml streptomycin, 10,000 units/ml
penicillin, and 25 g/ml amphotericin B. The cultures were maintained
for 7 days before the addition of viral vectors. In addition, a spontane-
ously immortalized HSC line established from experimental biliary
liver fibrosis (24) was maintained in culture in 6-well plates with low
glucose DMEM supplemented with 10% FBS and used for a transient
transfection experiment for AP-1 promoter activity.
Construction of Viral Vectors and Transduction of the Viral Vector-
mediated Genes—Full-length PPAR1 cDNA was cloned from pCMX-
PPAR into the transfer vector, subsequently allowing homologous
recombination with the pAdEasy-1 adenoviral plasmid containing GFP
(Stratagene, La Jolla, CA). GFP alone was used as a control for PPAR
(Ad.GFP). An adenoviral vector expressing a dominant negative mutant
form of PPAR with a GFP tag (Ad.dn.PPAR) was used. This
dn.PPAR carries the mutations at leucine and glutamic acid residues
in the conserved AF-2 region of the C-terminal end. These mutations
cause inhibition of recruitment of coactivators such as CBP and SRC-1
and ligand-dependent release of corepressors while promoting the basal
recruitment of corepressors (25). All adenoviral vectors (Ad.GFP,
Ad.PPAR, and Ad.dn.PPAR) were propagated using 293A cells in
high glucose DMEM medium containing 5% FBS and then purified
using cesium chloride gradient followed by dialysis for removing cesium
chloride. The viral particle was titrated by the TCID50 (tissue culture
infectious dose 50) method. Briefly, dilutions of viruses were incubated
with 293-A cells in 96-well plates, and the presence or absence of
cytopathic effect in each well was determined for titration. A multiplic-
ity of infection (MOI) of 100 was used for the efficient tansduction of
viral vector-mediated genes in activated HSC without any toxicity. HSC
were cultured for 7 days. On day 7 of culture, cells were transduced with
Ad.GFP, Ad.PPAR, or Ad.dn.PPAR or in combination using a total
MOI of 100. The next day, medium was changed and cultured for
another 4 days.
DNA Synthesis—DNA synthesis was determined by the rate of
[3H]thymidine incorporation into DNA. Activated HSC were cultured in
24-well plates (27,000 cells/well) and were transduced with Ad.GFP or
Ad.PPAR and cultured for an additional 5 days. On the 4th day after
infection, [methyl-3H]thymidine (PerkinElmer Life Sciences) (1 Ci/ml)
was added into each well and incubated overnight. After washing the
cells, DNA was precipitated with 10% trichloroacetic acid at 4 °C. After
several washes of the trichloroacetic acid precipitates, incorporation of
[3H]thymidine into DNA was determined by counting the radioactivity
of the precipitates using liquid scintillation counter. The count was
standardized by the cell number.
RNA Extraction and Real Time PCR—Total RNA was extracted from
HSC transduced with Ad.GFP, Ad.PPAR plus Ad.GFP, or Ad.PPAR
plus Ad.dn.PPAR using Trizol reagent (Invitrogen). Two micrograms
of RNA were reverse-transcribed at 37 °C for 60 min with Moloney
murine leukemia virus reverse transcriptase. For PCR analysis, the
synthesized cDNA was amplified using primers for PPAR, 1(I) pro-
collagen, TGF1, and -actin (16). For real time PCR, 2 ng of total RNA
was used in a 20-l reaction for reverse transcription for 50 min fol-
lowed by 40 cycles of PCR to produce PCR products using the TaqMan
Gold RT-PCR kit (Applied Biosystems, Foster city, CA). Probes were 5,6
carboxyl fluorescein amidite labeled at the 5-end and black hole
quencher-1 labeled at the 3-end (Biosearch Technologies Inc., Novato,
CA). Here, ABI 7700 SDS was used as a detection system. Each Ct value
was first normalized to the respective glyceraldehyde-3-phosphate de-
hydrogenase Ct value of a sample and subsequently to a control sample.
A difference in -fold was calculated from these Ct values.
Electrophoretic Mobility Gel Shift Assay—HSC nuclear proteins
(5–10 g) or PPAR, JunD, or RXR in vitro translated using the
coupled transcription/translation systems (Promega, Madison, WI)
were incubated in a reaction mixture (20 mM HEPES, pH 7.6, 100 mM
KCl, 0.2 mM EDTA, 2 mM dithiothreitol, 20% glycerol, 200 g/ml
poly(dI-dC)) on ice for 15 min and further incubated with 1–2 ng of
-32P-labeled doubled-stranded ARE-7 (the PPAR response element
from the adipocyte fatty acid-binding protein gene) or AP-1 element (26)
for an additional 30 min. The reaction mixture was then resolved on a
6% nondenaturing polyacrylamide gel in 4 TBE (45 mM Tris, 45 mM
boric acid, 1 mM EDTA). The gel was dried and subjected to autoradiog-
raphy. For a supershift analysis, polyclonal antibodies against c-Fos,
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FosB, JunD, or PPAR (Santa Cruz Biotechnology, Inc., Santa Cruz,
CA) were added and incubated for an additional 20 min after the 30-min
incubation.
Transient Transfection and Reporter Gene Assay—To determine
whether PPAR expressed by the adenoviral vector induces the PPAR
response element (PPRE) promoter activity, HSC were transiently
transfected with a PPRE-luciferase construct (tk-PPRE  3-luciferase)
using Targefect F-2 (Advanced Targeting Systems, San Diego, CA). To
examine the effect of PPAR expression on AP-1 activity, HSC trans-
duced with Ad.PPAR or Ad.GFP were transiently transfected with an
AP-1 luciferase construct containing seven repeats of TGACTAA from
the 12-O-tetradecanoylphorbol-13-acetate-responsive element (Strat-
agene, La Jolla, CA). We also examined the effects of CBP/p300 expres-
sion on the PPAR-mediated effect on AP-1 by co-transfecting the
Ad.GFP or Ad.PPAR HSC line with a CBP/p300 expression plasmid (a
kind gift from Dr. Stallcup, University of Southern California). For the
determination of transfection efficiency, Renilla phRL-TK vector was
used (Promega, Madison, WI). For transfection, 10-day cultures of HSC
or HSC line in 6-well plates (70,000 cells/well; 3 days after infection
with a viral vector) were incubated with 2 g of each reporter construct,
0.02 g of Renilla phRL-TK, and 2 l of F-2 reagent in 1 ml of serum-
free high glucose DMEM. Two h later, 1 ml of DMEM with 10% FBS
was added to achieve the final FBS concentration of 5% for overnight
incubation. On the next day, the medium was changed to DMEM with
10% FBS, and the cells were incubated for another 30 h. The cell lysate
was collected for determination of both firefly and Renilla luciferase
activities using the Dual-Luciferase reporter assay system (Promega).
The results were normalized by Renilla luciferase activity.
Morphological Analysis—To investigate the effects of PPAR on the
HSC morphology, 7-day cultured HSC were transduced with Ad.GFP,
Ad.PPAR plus Ad.GFP, or Ad.PPAR plus Ad.dn.PPAR using a total
MOI of 100 of virus and cultured for an additional 5 days. The cells were
examined under a fluorescent microscopy and photographed for docu-
mentation. The cells were also fixed in 3% paraformaldehyde in a
phosphate buffer for 1 h and washed with a phosphate buffer. Stress
fibers were subsequently stained with rhodamine-labeled phalloidin for
30 min and washed with a phosphate buffer, and differential interfer-
ence contrast images were acquired to assess the effects of PPAR
expression.
Retinyl Palmitate Measurement—To investigate the effect of PPAR
on the formation of intracellular lipid droplets, the cells were cultured
with retinol (5 M), palmitate (100 M), or both for 48 h and stained with
Oil Red O solution (in 60% isopropyl alcohol) for 20 min followed by
counterstaining with hematoxylin. The stained slides were examined
and photographed using an inverted light microscope. For chemical
quantification of retinyl palmitate (a predominant vitamin A form
stored in HSC), lipids were extracted with methanol and hexane from
HSC treated with both retinol and palmitate (27). Retinyl palmitate in
the hexane-extractable lipid phase was analyzed by reverse-phase high
pressure liquid chromatography (HPLC) with the wavelength detector
set at 325 nm. To prepare samples for HPLC analysis, solvent was
evaporated from portions of lipid extracts in a 37 °C water bath using a
gentle stream of N2. Samples were resolubilized in 1:1 methanol-chlo-
roform solvent before HPLC. For data acquisition and peak area inte-
gration, the Winflow software package system (Inus Systems, Tampa,
FL) was used. The data were standardized with the cell number. The
HPLC analyses were performed at the Cell Biology Core of the USC
Research Center for Liver Diseases.
Western Blot Analysis of Cellular Proteins—HSC were cultured in a
100-mm dish for 7 days. On day 7, HSC were transduced with Ad.GFP or
Ad.PPAR using an MOI of 100 and cultured for additional 5 days. On day
12, cells were washed with PBS once and lysed with a lysis buffer (20 mM
Tris-HCl, pH 7.6, 20 mM NaF, 20 -glycerophosphate, 0.5 mM Na3VO4, 2.5
metabisulfite, 5 mM benzamidine, 1 mM EDTA, 0.5 mM EGTA, and 300
NaCl, with 10% glycerol and protease inhibitors and 1% Triton X-100).
The lysates were stored at 80 °C until assayed. An equal amount of the
whole cell protein (100 g) was separated by SDS-PAGE and electro-
blotted to nitrocellulose filters. Proteins were detected by incubating the
filter with monoclonal anti--smooth muscle actin (Sigma), rabbit poly-
clonal anti-type I collagen (Rockland Inc., Gilbertsville, PA), anti-PPAR,
or anti-JunD antibody (Santa Cruz Biotechnology) at a concentration of
0.2–2 g/10 ml in TBS (100 mM Tris-HCl, 1.5 M NaCl, pH 7.4) with 5%
nonfat milk followed by incubation with a horseradish peroxidase-conju-
gated secondary antibody (Santa Cruz Biotechnology) at 1 g/10 ml.
Proteins were detected by a chemiluminescent method using the PIERCE
ECL kit (Amersham Biosciences).
JNK Assay—To assay the activity of JNK, HSC transduced with
Ad.GFP or Ad.PPAR were lysed for collection of the whole cell proteins
as described above. Each 100 g of lysate was used to immunoprecipi-
tate with 2 g of anti-JNK1 antibody (Santa Cruz Biotechnology).
Immunoprecipitates were then incubated with 2 g of the N-terminal
peptide of c-Jun (Santa Cruz Biotechnology) in 30 l of kinase reaction
buffer (20 mM Tris-HCl, pH 7.5, 20 mM MgCl2, 2 mM dithiothreitol)
containing 20 M ATP and [-32P]ATP (0.5 Ci) for 1 h at 30 °C. The
protein mixture was resolved by 10% SDS-PAGE followed by a transfer
onto a nitrocellulose membrane and exposure of the membrane to a
PhosphorImager. Phosphate incorporated into c-Jun was visualized.
Total JNK levels were determined by immunoblot analysis.
PPAR Immunoprecipitation and JunD Immunoblot Analysis—In
order to assess the protein-protein interaction between PPAR and
JunD, in vitro translated PPAR and JunD were incubated with an
anti-PPAR antibody (Santa Cruz Biotechnology) for 2 h. Protein A/G
beads were added and incubated for another 24 h. Beads were washed
three times and subjected to SDS-PAGE. Blots were probed with rabbit
polyclonal anti-JunD antibody (2 g/10 ml) in TBS containing 5% non-
fat milk. Horseradish peroxidase-conjugated secondary antibody (1
g/10 ml) was added and incubated followed by detection of JunD with
the ECL reagent as described.
Glutathione S-Transferase (GST) Pull-down Assay—Expression vec-
tors for GST, GST-PPAR (pGEX-4T2 and pGEX-4T2-PPAR provided
by Dr. Akira Sugawara, Tohoku University School of Medicine, Sendai,
Japan), and GST fusion proteins of PPAR deletion mutants (pGEX-
4T1-PPAR deletion mutants provided by Dr. Shigeaki Kato, Univer-
sity of Tokyo, Tokyo, Japan) were produced in Escherichia coli BL21.
The glutathione beads were coated with the fusion proteins by incubat-
ing both together overnight at 4 °C. JunD protein was translated in
vitro from pcDNA3-mJunD plasmid (kindly provided by Dr. Sunita K.
Agarwal, National Institutes of Health, Bethesda, MD) in the presence
of [35S]methionine using the TNT-T7-coupled reticulocyte lysate system
(Promega, Madison, WI). The binding assay was conducted by incubat-
ing overnight at 4 °C the fusion protein-coated beads with 25 l of the
in vitro translation reaction in a 300-l total volume of a NETN buffer
(20 mM Tris, pH 8, 100 mM NaCl, 1 mM EDTA) containing 0.01%
Nonidet P-40. Beads were washed four times with NETN (0.01%) and
analyzed by SDS-PAGE and autoradiography.
Statistical Analysis—All numerical data were expressed as means 
S.D. The significance of the difference between two groups was assessed
using a standard t test.
RESULTS
Forced Expression of PPAR and PPRE Transactivation by
Ad.PPAR in Activated HSC—We first validated the forced
expression of PPAR in culture-activated HSC transduced with
Ad.PPAR by Western blot analysis. Ad.GFP-transduced HSC
as a control had no detectable PPAR (Fig. 1A), confirming the
previous finding in our and other laboratories that activation of
HSC results in depletion of this transcription factor (16). As
expected, Ad.PPAR infection indeed resulted in the expres-
sion of PPAR in HSC (Fig. 1A). Further, the forced PPAR
expression increased PPRE promoter activity by 250-fold as
determined by transfection of HSC with a PPRE-luciferase
reporter gene containing three copies of the PPRE linked to the
thymidine kinase promoter (Fig. 1B).
Morphological Changes Induced by PPAR Expression—We
examined whether the restoration of PPAR expression
affected the morphological features of activated HSC. Culture-
activated HSC transduced with Ad.GFP exhibited a large, flat-
tened polygonal shape, the typical cell morphology of culture-
activated primary HSC (Fig. 2A). Infection with Ad.PPAR
resulted in retracted and reduced cytoplasm with the reappear-
ance of dendritic processes resembling the more quiescent HSC
phenotype (Fig. 2B). Using an MOI of 50, the expression of the
wild-type PPAR (Ad.PPAR) reproduced the similar mor-
phological changes (Fig. 2C), and this effect was completely
blocked by the co-infection of the cells with an adenoviral
vector expressing a dominant negative mutant of PPAR
(Ad.dn.PPAR, MOI 50) (Fig. 2D). For the control, we used an
MOI of 50 of Ad.GFP, maintaining the total viral MOI of 100.
Further, we tested the effect of PPAR expression on actin
cytoskeleton. The stress fibers were labeled with rhodamine-
phalloidin. Ad.GFP-transduced cells showed prominent actin
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stress fibers in a pattern typically observed in activated HSC
(Fig. 2E). The cells expressing PPAR showed an aberrant
pattern of reduced stress fibers (Fig. 2F). This change in the
stress fibers was also blocked by the co-infection with Ad.dn.
PPAR (Fig. 2H). In summary, these results demonstrate that
the forced expression of PPAR reverses the morphology of
activated HSC to that of more quiescent HSC, and this effect is
mediated by trans-activation of PPRE promoters as dn.PPAR
effectively abrogates the effect.
PPAR Expression Decreases HSC Proliferation—One of the
most obvious and important parameters of HSC activation is
increased DNA synthesis. We have examined next whether the
forced PPAR expression inhibits this parameter. Forced ex-
pression of PPAR in activated HSC caused a 70% inhibition in
HSC DNA synthesis compared with that found in Ad.GFP-
infected HSC controls (Fig. 3A).
PPAR Expression Inhibits Expression of HSC Activation
Marker Genes—To further validate the reversal of HSC activa-
tion at the functional level, we next examined the effects of
PPAR expression on mRNA expression of 1(I) procollagen
and TGF1, the two bona fide activation markers expressed by
HSC (28, 29). Real time PCR analysis revealed that 1(I) pro-
collagen and TGF1 mRNA levels were significantly reduced
by 60 and 40%, respectively, in Ad.PPAR-transduced HSC as
compared with Ad.GFP-transduced cells, whereas the PPAR
mRNA level showed an expected robust increase (Fig. 3B). We
also performed immunoblot analyses for -smooth muscle actin
and type I collagen and demonstrated that the expression of
both proteins were inhibited in Ad.PPAR-transduced cells
compared with Ad.GFP-transduced cells (Fig. 3C). Densitomet-
ric and statistical analyses of three sets of blots revealed that
the expression of -smooth muscle actin and type I collagen
proteins in Ad.PPAR-transduced cells was reduced to 31.7 
28.3% (p  0.05) and 30.0  15.7% (p  0.05) of those in
Ad.GFP-transduced cells, respectively. These results unequiv-
ocally confirm inhibition of myofibroblastic activation of HSC
by forced PPAR expression.
PPAR Expression Allows HSC to Restore Their Ability to
Accumulate Retinyl Esters—One of the characteristic functions
of the quiescent HSC is the storage of vitamin A, which is
significantly diminished in activated HSC (30). Thus, we ex-
amined whether the forced expression of PPAR by Ad.PPAR
restored the ability of HSC to accumulate retinyl esters. For
this, we have added retinol (5 M), palmitate (100 M), or both
to the cultures of Ad.PPAR- or Ad.GFP-transduced HSC. In
Ad.GFP-transduced cells, the addition of retinol or/and palmi-
tate did not significantly modify the lipid staining (Fig. 3D, left
panel). Ad.PPAR infection alone slightly increased the lipid
staining regardless of whether they were treated with retinol
FIG. 1. Adenovirus-mediated expression of PPAR. A, immuno-
blot analysis of nuclear proteins (25 g each) from HSC transduced with
Ad.GFP and Ad.PPAR confirms the depletion of PPAR in culture-
activated former cells and sufficient expression of the transcription
factor in the latter cells. Immunoblot for -tubulin is shown as a control.
B, PPAR-driven PPRE promoter activity is conspicuously increased in
Ad.PPAR-transduced HSC as compared with Ad.GFP-transduced cells
as shown by the transient transfection experiment with the PPRE-
luciferase construct. *, p  0.05 (n  6) compared with the Ad.GFP-
transduced cells.
FIG. 2. Forced expression of PPAR causes the reversal of the
activated morphology to the quiescent phenotype. The morphol-
ogy of the activated HSC is visualized by GFP fluorescence in culture-
activated HSC transduced with the different adenoviral vectors, all
expressing GFP (A–D). Ad.GFP-transduced cells show typical flattened,
polygonal morphology of culture-activated HSC (A). PPAR-expressing
cells show retracted cytoplasm and the reappearance of dendritic pro-
cesses, the morphologic features that resemble the quiescent HSC phe-
notype (B). Using 50 MOI each of Ad.PPAR and Ad.GFP, a similar
phenotype is attained (C), and this effect is abrogated by concomitant
infection with Ad.dn.PPAR (D). To examine the effect of PPAR ex-
pression on actin cytoskeleton, stress fibers were labeled with rhoda-
mine phalloidin. Ad.GFP-transduced, activated HSC showed prominent
actin stress fibers (E) that are reduced in Ad.PPAR-transduced HSC
(F). This effect is also blocked by Ad.dn.PPAR infection (H versus G).
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or palmitate alone (Fig. 3D, middle panel). However, the addi-
tion of both retinal and palmitate caused a conspicuous in-
crease in the Oil Red O staining in these cells (Fig. 3D, middle
bottom panel). The staining looked brownish in some cells due
probably to microvesicular nature of lipid/retinoid storage in
HSC. This type of lipid accumulation resembled the quiescent
HSC cultured only for 1 day on plastic. The lipid accumulation
caused by PPAR was partially blocked by the expression of
FIG. 3. PPAR inhibits activation
markers and restores the capacity to
accumulate retinyl esters. A, Ad.
PPAR infection inhibits DNA synthesis
as determined by incorporation of [3H]thy-
midine. Note that PPAR expression
causes a 70% inhibition of DNA synthesis.
*, p  0.05 (n  3). B, Ad.PPAR infection
causes an expected increase in PPAR
mRNA while inhibiting mRNA expression
of 1(I) procollagen (60%) and TGF1
(40%) in culture-activated HSC as de-
termined by Taqman PCR. *, p  0.05
(n  3). C, expression of -smooth muscle
actin (-SMA) and type I collagen (Colla-
gen) are inhibited in Ad.PPAR-trans-
duced HSC compared with Ad.GFP-trans-
duced cells as assessed by immunoblot
analysis. The equal protein loading is de-
picted by protein staining shown below
each blot. D, accumulation of intracellular
lipids is slightly increased by PPAR ex-
pression (Ad.PPAR  Ad.GFP) in the
absence or presence of retinol or palmi-
tate (top three panels of the middle col-
umn) as determined by staining with Oil
Red O. Treatment of these cells with both
retinol and palmitate results in marked
accumulation of lipids, resembling quies-
cent HSC (bottom, middle column). These
effects on intracellular lipids are partially
blocked by the concomitant infection with
Ad.dn.PPAR (right column).
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dn.PPAR (compare the bottom panel of the middle and last
column). To validate that the accumulation of lipids really
reflected increased storage of retinyl palmitate, the major spe-
cies of stored retinyl esters in HSC in vivo (23), we analyzed the
content of the retinyl ester in extracted lipids using reverse
phase HPLC. Indeed, this analysis demonstrated a 3-fold in-
crease in the content of retinyl palmitate in Ad.PPAR-trans-
duced HSC (9.0  0.92 g/106 cells) as compared with Ad.GFP-
transduced cells (2.9  1.23 g/106 cells) under the treatment
of retinol and palmitate.
Reduced AP-1 Binding in PPAR-expressing HSC—The re-
sults presented so far convincingly demonstrate that the forced
expression of PPAR in culture-activated HSC induces the
reversal of the cell phenotype to that of quiescent HSC at both
morphologic and biochemical levels. In order to investigate this
effect at a more molecular level and to explore the mechanisms
involved, we assessed the effects of the forced PPAR expres-
sion on AP-1 binding, the parameter that is known to char-
acterize and underlie many biochemical aspects of activated
HSC (31). Nuclear extracts were prepared from Ad.GFP- and
Ad.PPAR-transduced HSC, and an electrophoretic mobility
shift assay was performed. As a positive control, PPRE binding
by PPAR was assessed using an ARE-7 probe (a PPRE from
the adipocyte fatty acid-binding protein gene), which more
specifically binds PPAR over PPAR (32). As shown in Fig.
4A, culture-activated HSC transduced with Ad.GFP were de-
pleted of PPAR binding to PPRE, which was significantly
increased in PPAR-expressing cells. The specificity of binding
was supported by a supershift analysis using anti-PPAR an-
tibody (the last lane in Fig. 4A). Quiescent HSC (HSC cultured
for 1 day) have minimal AP-1 binding activity, which is mark-
edly increased on days 3 and 7 in culture (Fig. 4B). The robust
AP-1 binding in activated HSC transduced with Ad.GFP was
decreased significantly in the PPAR-expressing cells (Fig. 4B).
FIG. 4. PPAR expression inhibits JunD binding to AP-1 and AP-1 promoter activity. A, PPAR binding to the PPRE (ARE7) probe is
increased in nuclear extracts prepared from HSC transduced with Ad.PPAR as assessed by an electrophoretic mobility gel shift assay. Note that
Ad.GFP-transduced cells have no appreciable binding, confirming the depletion of PPAR in culture-activated HSC. The last lane shows supershift
with anti-PPAR antibody (Ab). B, in contrast to PPAR binding, AP-1 binding is nearly absent in the quiescent HSC (1-day HSC) and increases
as HSC become activated on day 3 and day 7 in culture (first panel). AP-1 binding is reduced in HSC transduced with Ad.PPAR (middle panel).
The last lanes of the middle and right panels show successful supershift of the AP-1 binding complex with anti-JunD antibody but not with
anti-c-Fos or anti-FosB antibody (second and third lanes of the right panel). C, AP-1 promoter activity is decreased in Ad.PPAR-transduced HSC
line as demonstrated by transient transfection experiments using the AP-1 promoter luciferase construct. The data were standardized by the
transfection efficiency as determined by Renilla luciferase activity. *, p  0.05 (n  6). D, overexpression of CBP/p300 does not prevent
PPAR-induced suppression of AP-1 promoter activity. The HSC line was co-transfected with a pCMX or PPAR expression vector in the absence
or presence of a p300 expression vector. Note that this experiment confirms the inhibition of AP-1 promoter activity by PPAR (pCMX versus
PPAR). Overexpression of p300 increases AP-1 promoter activity in both pCMX- and PPAR-transfected cells. However, the magnitude of
PPAR-mediated inhibition of AP-1 is not altered by p300 overexpression. *, p  0.05 (n  3).
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The major components of AP-1 complexes in activated HSC
were previously reported to be JunD, c-Fos, and FosB (33). A
supershift analysis using antibodies against c-Fos, FosB, and
JunD revealed that JunD was the main component of the AP-1
complex shown to bind to the DNA (Fig. 4B). Thus, these
results demonstrate that PPAR decreases JunD binding to the
AP-1 site and suggest that this may be of potential significance
in inhibiting DNA synthesis and expression of activation
marker genes such as TGF1 and 1(I) procollagen.
PPAR Expression Suppresses AP-1 Promoter Activity—
Next, we examined whether the decreased AP-1 binding by
PPAR is associated with a decreased AP-1 promoter activity
in Ad.PPAR-transduced HSC. Transient transfection using an
AP-1 promoter luciferase construct showed that the AP-1 pro-
moter activity was indeed reduced by 40% in the HSC line
transduced with Ad.PPAR as compared with Ad.GFP-trans-
duced cells (Fig. 4C).
Overexpression of p300 Co-activator Does Not Ameliorate
PPAR-mediated Inhibition of AP-1 Promoter Activity—Ex-
pression of one transcription factor may affect the activity of
another trans-acting factor via a competition for a shared co-
activator. In fact, p300 is a co-activator important for optimal
transactivation of the promoter dependent on AP-1 (34) as well
as that of the PPAR-driven PPRE promoter (35, 36). There-
fore, PPAR-mediated inhibition of AP-1 activity may be a
consequence of a competition for the limiting level of p300. To
test this possibility, HSC cell line was transiently co-trans-
fected with the AP-1 luciferase construct, a PPAR expression
vector or empty vector in the presence or absence of a p300
expression vector. In this experiment, we first confirmed that
expression of PPAR inhibited AP-1 promoter activity (Fig. 4D,
first two bars). Expression of p300 increased AP-1 promoter
activity regardless of whether PPAR was co-expressed, indi-
cating that p300 indeed serves as a co-activator for AP-1 (Fig.
4D, last two bars). However, the expression of p300 did not
affect the magnitude of inhibition of AP-1 promoter caused by
PPAR (Fig. 4D). Therefore, the expression of p300 did not
rescue the cells from the suppressive effect of PPAR on AP-1
promoter activity, suggesting that p300 was not the limiting
factor for AP-1 transcription in the presence of PPAR.
Inhibited AP-1 Binding Is Not Due to a Change in JunD
Expression or JNK Activity—To determine the mechanisms
underlying inhibited AP-1 DNA binding in Ad.PPAR-trans-
duced HSC, we examined whether JunD mRNA or protein level
was diminished in the cells. As shown in Fig. 5A, neither JunD
mRNA nor JunD protein level was altered in Ad.PPAR-trans-
duced cells. Since JNK activity is required for phosphorylation
of JunD for its activation, we tested next whether JNK activity
was altered by forced PPAR expression. JNK activity, as as-
sessed by phosphorylation of GST-c-Jun, was not reduced in
Ad.PPAR-transduced HSC (Fig. 5B). Thus, these results sug-
gest that expression and activation of JunD are not decreased
by PPAR expression in activated HSC.
The Direct Addition of PPAR Dose-dependently Decreases
JunD Binding to AP-1 Site—To test the possibility of direct
inhibition of JunD binding by PPAR, we tested whether in
vitro translated PPAR inhibited the binding of in vitro trans-
lated JunD to the AP-1 site. As depicted in Fig. 6A, the addition
of PPAR dose-dependently reduced JunD-mediated AP-1
binding. To confirm this effect using nuclear extracts from
culture-activated HSC as an abundant source of JunD protein,
an increasing amount of in vitro translated PPAR was added
to the extracts. This addition also decreased endogenous JunD
binding in a dose-dependent fashion (Fig. 6B). These results
suggested that PPAR directly interacted with JunD to inhibit
its binding to the AP-1 site.
Neither PPAR-selective Ligand nor RXR Enhances the In-
hibitory Effect of PPAR on JunD Binding—Next, we deter-
mined whether the addition of a PPAR-selective ligand
(GW1929) potentiated the inhibitory effect of PPAR on the
binding of endogenous JunD to the AP-1 site. As shown in Fig.
6C (lane 2 versus lane 4), no additive effects of GW1929 were
observed. These findings were also confirmed by an experiment
using in vitro translated JunD (Fig. 6D, lane 2 versus lane 4).
Since RXR is a heterodimeric partner of PPAR, we also
assessed whether RXR further decreased PPAR-mediated
JunD binding to the AP-1 site. Interestingly, RXR alone de-
creased the binding of endogenous JunD (Fig. 6C, lane 1 versus
lane 5) but not that of in vitro translated JunD (Fig. 6D, lane 1
versus lane 5) to the AP-1 site, suggesting the requirement of
additional endogenous factor(s) for RXR-mediated inhibition
of AP-1 binding. However, the addition of RXR together with
PPAR did not promote the inhibitory effect of PPAR on JunD
binding (Fig. 6, C and D, lane 2 versus lane 6).
PPAR and a Dominant Negative Mutant of PPAR (dn.
PPAR) Equally Inhibit AP-1 Binding—We next tested
whether dn.PPAR that blocked the morphologic effects of the
wild type PPAR could modify the inhibitory effect of PPAR
on AP-1 binding. Here adenoviral-mediated expression of
PPAR was again shown to inhibit AP-1 binding (data not
shown). Interestingly, overexpression of dn.PPAR alone also
rendered the same inhibitory effect. Using 50 MOI each, the
wild type PPAR caused a moderate inhibition of AP-1 binding,
and this was further suppressed by the addition of Ad.dn.
PPAR (data not shown). Both PPAR and dn.PPAR bound to
the ARE7 probe with the same efficiency confirming the origi-
nal finding that the mutations in the AF-2 region of PPAR did
not affect DNA binding but rather inhibited PPRE transacti-
vation (25). These results demonstrate that dn.PPAR equally
inhibits AP-1 binding, and this inhibition does not appear to
involve the AF-2 region.
PPAR Physically Interacts with JunD—The direct interac-
tion between PPAR and JunD was suggested by the aforemen-
tioned results, and this notion was tested by co-immunoprecipi-
tation and GST pull-down assays. For the former, in vitro
translated PPAR and JunD were incubated, PPAR was im-
munoprecipitated with the specific antibody, and the precipi-
FIG. 5. Neither JunD expression nor JNK activity is altered by
PPAR. A, to examine the mechanisms of reduced AP-1 binding by
PPAR, the effects of PPAR overexpression on JunD mRNA and pro-
tein levels in HSC were assessed by RT-PCR and immunoblot analyses.
Note that PPAR expression does not affect mRNA and protein levels of
JunD. B, PPAR expression also does not alter JNK activity and JNK
protein levels as assessed by phosphorylation of GST-c-Fos and immu-
noblot analysis, respectively.
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tates were resolved on a gel and blotted with anti-JunD anti-
body. As shown in Fig. 7A, this procedure detected a band (lane
2) corresponding to the size of in vitro translated JunD (lane 1),
whereas no expression of PPAR (PCMX; lane 3) or immuno-
precipitation with a nonimmune IgG (lane 4) failed to detect
this band, suggesting a direct interaction between PPAR and
JunD. For the GST pull-down assay, in vitro translated, 35S-
labeled JunD was detected when GST-PPAR was pulled down
with GSH beads from the incubation mixture of a JunD expres-
sion vector and the GST-PPAR fusion protein (Fig. 7B, lane 5)
but not from the mixture of the empty vector and the fusion
protein (lane 3) or that of the JunD vector with no fusion
protein (lane 4). These results supported the notion that
PPAR and JunD indeed achieve a physical interaction, and
this process interferes with JunD binding to the AP-1 element.
Assessment of the JunD-interacting Domain Using GST-
PPAR Deletion Mutants—To identify the domain of PPAR
that interacts with JunD, 35S-labeled JunD was incubated with
the following PPAR deletion mutants: full-length, the A/B
region only (residues 1–138); A/B and C regions (residues
1–203); A/B, C, and D regions (residues 1–311); D and E regions
(residues 204–506); and E region only (residues 312–506). The
pull-down results demonstrated that JunD interacted with the
1–203 or 1–311 mutant but not with the 1–138 mutant, sug-
gesting that the C region (residues 139–203) is the primary
domain for the interaction (lanes 5 and 6). The E region (resi-
dues 312–506) of PPAR sometimes showed a much weaker
interaction with JunD (data not shown).
DISCUSSION
The present study is the first to test whether forced expres-
sion of PPAR, a nuclear receptor that is depleted in activated
HSC, reversed the activated phenotype of the cells to the qui-
escent phenotype. Indeed, the adenovirus-mediated restoration
of PPAR resulted in the reappearance of morphologic features
of quiescent HSC and inhibition of functional parameters for
HSC activation such as increased DNA synthesis, the expres-
sion of -smooth muscle actin, type I collagen, and TGF1.
More importantly, the forced PPAR expression restored the
ability of the cells to accumulate retinyl palmitate, the unique
and specific function of quiescent HSC in vivo. These results
support our underlying hypothesis that PPAR is required for
the maintenance of the quiescent phenotype of HSC much like
its requirement for adipocyte differentiation. This hypothesis
was based on several lines of experimental evidence. Preadipo-
FIG. 6. The addition of increasing amounts of in vitro translated
PPAR dose-dependently decreases the binding of in vitro translated
JunD (A) or endogenous JunD in HSC nuclear extracts (NE) (B) to the
AP-1 probe as assessed by an electrophoretic mobility gel shift assay.
The addition of in vitro translated RXR or the PPAR-specific ligand
(GW1929) failed to promote the inhibition of the binding of endogenous
JunD (C) or in vitro translated JunD (D) to the AP-1 probe. RXR alone
decreases the AP-1 binding by endogenous JunD (lane 5 of C) but not
that by in vitro translated JunD (lane 5 of D).
FIG. 7. PPAR interacts with JunD protein. A, in vitro translated
JunD and PPAR were incubated together, and PPAR was immuno-
precipitated from the mixture. The precipitates were subjected to an
immunoblot analysis for JunD. Note the presence of a JunD band in the
second lane, whereas JunD immunoblots for the precipitate of the
mixture containing no PPAR (PCMX) and immunoprecipitation (IP)
with nonimmune IgG showed no band. The first lane shows a positive
control where in vitro translated JunD was immunoprecipitated with
anti-JunD antibody followed by immunoblotting with the same anti-
body. B, for the GST pull-down assay, in vitro translated, 35S-labeled
JunD was detected when GST-PPAR was pulled down with GSH beads
from the incubation mixture of a JunD expression vector and the
GST-PPAR fusion protein (lane 5) but not from the mixture of the
empty vector and the fusion protein (lane 3) or that of the JunD vector
with no fusion protein (lane 4). C, full-length and five truncated GST-
PPAR fusion proteins were incubated with in vitro translated 35S-
labeled JunD. 35S-Labeled JunD was detected when region 1–203 (lane
5) or region 1–311 (lane 6) but not region 1–138 (lane 4) was used.
Further, the 204–506 region did not show any 35S-labeled JunD (lane 7)
band, suggesting that the region between 139 and 203 of PPAR (C
region; DNA binding region) is the primary region for the interaction
with JunD.
PPAR and Hepatic Stellate Cells 11399
cytic fibroblasts can be differentiated into mature adipocytes
when cultured in the condition that promotes induction of
transcription factors that are essential for induction of adipo-
cyte-specific genes. One such factor is PPAR that is considered
as a master regulator for adipogenesis (15). This adipogenic
differentiation is inhibited by growth factors (platelet-derived
growth factor and TGF/epidermal growth factor) or cytokines
(tumor necrosis factor  and leptin) that appear to impair the
activities of PPAR or other adipogenic transcription factors
(37). Interestingly, these same soluble factors are also impli-
cated in activation of HSC, and this activation is characterized
by transdifferentiation of lipid-rich quiescent HSC to lipid-
devoid myofibroblastic cells (38, 39). This analogy between
adipocyte differentiation and HSC transdifferentiation is fur-
ther supported by the fact that HSC express adipocyte- or
preadipocyte-specific genes such as leptin (13). In fact, three
laboratories including our own reported in 1999 that in vitro
(16, 18) or in vivo (16, 17) activated HSC had reduced PPAR
levels and activities, and the treatment of activated HSC in
vitro with the natural or synthetic ligands of PPAR inhibited
the diverse fibrogenic parameters of the cell activation (16).
These studies were followed by an in vivo study by Galli et al.
(17), who demonstrated effective prevention of the initiation of
liver fibrosis and progression of preexisting liver fibrosis using
toxic (dimethylnitrosamine or carbon tetrachloride) and chole-
static (bile duct ligation) animal liver fibrosis models and two
PPAR ligands (pioglitazone and rosiglitazone) (17). Thus,
these findings collectively point toward the role of PPAR as an
anti-fibrogenic regulator in HSC that becomes depleted in ac-
tivation of the cells. Indeed, the results presented in the cur-
rent study definitively demonstrate the direct actions of PPAR
to reverse the activated phenotype without the use of exoge-
nous ligands that are known to have receptor-independent
effects as discussed in the Introduction (19–22). Further, our
findings have far reaching implications beyond the therapeutic
significance of PPAR for liver fibrosis. They address the fun-
damental question of whether HSC transdifferentiation is
analogous to adipocyte differentiation. Our previous analysis of
the expression of PPAR isoforms by an RNase protection
assay demonstrated detection of the ubiquitous 1 but not the
adipocyte-specific 2 isoform, indicating that HSC may not
completely share the adipocyte phenotype (16). However, our
present findings support a conclusion that similar regulatory
mechanisms to those in adipocyte differentiation may exist in
HSC transdifferentiation.
Another interesting finding from our study was that PPAR
facilitated both PPRE-dependent and -independent regulation
of HSC. The morphologic reversal to the quiescent character-
istics was dependent on PPRE promoter transactivation, since
dn.PPAR that exerts its effects at the promoter level blocked
this morphologic effect. On the other hand, PPAR-mediated
inhibition of AP-1 promoter activity appeared to be at the level
upstream of transcription and to be due to a direct interaction
between PPAR and JunD and consequent inhibition of JunD
binding to the AP-1 site. There are numerous examples for this
mode of negative cross-coupling between transcription factors.
RAR and RXR are shown to inhibit AP-1 promoter activity via
their ligand-dependent interactions with c-Jun (40) at their
ligand binding domain. We also demonstrated inhibition of
JunD binding to DNA by RXR when nuclear extracts but not in
vitro translated JunD was used as the source of JunD. This
differential effect is due probably to the presence or absence of
an RXR ligand. In terms of PPAR-mediated interactions, it is
shown to physically interact with Smad3 to serve as a mecha-
nism underlying ligand-mediated inhibition of expression of
connective tissue growth factor in TGF-treated aortic smooth
muscle cells (41). Further, PPAR interacts with Sp1 and in-
hibits Sp1-mediated transcription of thromboxane receptor
gene in vascular smooth muscle cells (42). PPAR has most
recently been shown to interact with NF-B via PGC-2, an
AF-1-specific co-activator for PPAR. This complex formation
inhibits PPAR binding to DNA, and this mode of cross-cou-
pling is suggested to play a role in shifting cellular differenti-
ation of pluripotent mesenchymal stem cells to osteoblasts from
adipocytes (43). They further showed that the DNA binding
region of PPAR was the interacting domain for p65. Our
results with the deletion mutants also demonstrate that the
same region was responsible for the interaction with JunD.
However, in our study, in vitro translated PPAR and JunD
physically interacted without the presence of ligands or co-
activators. Even when we used HSC nuclear extracts as the
source of JunD, the inhibition of AP-1 binding by in vitro
translated PPAR was not promoted by the addition of the
PPAR-selective ligand or in vitro translated RXR, suggesting
that the mechanisms of the protein-protein interaction in our
experimental setting are different from previous studies and do
not require either a heterodimer formation or activation of the
complex with a ligand. Further, our finding that dn.PPAR
equally inhibited AP-1 binding suggests that this inhibition
does not require AF-2-specific co-activators. Inhibition of JunD
binding by PPAR shown in our study has direct physiological
implications in regulation of HSC activation, since JunD/AP-1
activity is shown to be important in expression of TGF (40),
collagen (44), matrix metalloproteinase (8), tissue inhibitor of
matrix metalloproteinase-1, and interleukin-6 (9) gene tran-
scription. Indeed, suppressed JunD binding by adenovirus-
mediated expression of PPAR resulted in inhibition of both
TGF and 1(I) procollagen gene expression in HSC (Fig. 3B).
The most striking phenotypic change facilitated by PPAR
was the restoration of the ability of HSC to accumulate retinyl
palmitate when retinol and palmitate were presented to the
cells. Since Ad.PPAR infection alone or the concomitant addi-
tion of palmitate only slightly induced lipid accumulation, it
appears unlikely that adipogenic differentiation was fully at-
tained by these experimental conditions. Rather, these results
suggest that PPAR expression promoted the HSC-specific
function of storing retinyl esters. It is interesting that this
phenotype was partially blocked with dn.PPAR, suggesting
that induction of PPRE-driven genes may be partly involved.
The understanding of the mechanisms underlying this effect
requires further analysis of the genes involved in retinol ester-
ification in HSC. Similarly, the morphologic reversal to the
quiescent phenotype by PPAR was dependent on the PPRE
activity, suggesting the involvement of genes regulated by
PPRE in attaining the morphologic effects. Further analysis of
the genes involved in cytoskeletal organization and cell adhe-
sion will be required to better understand the molecular mech-
anisms of the morphologic effects.
In summary, our results demonstrate that culture-activated
HSC can be phenotypically and functionally reversed to the
cells with the quiescent phenotype by forced expression of
PPAR. These results conceptually support the importance of
PPAR in the maintenance of the quiescent HSC phenotype.
We also demonstrate a physical interaction of PPAR with
JunD but not alterations in JunD expression or JNK activity as
part of the mechanisms underlying inhibition of JunD binding
to DNA and AP-1 promoter activity. Our findings support the
notion that PPAR itself is the important effector molecule for
controlling transdifferentiation of HSC. Whether and how
other adipogenic transcriptional programs are involved in reg-
ulation of HSC are intriguing questions that need to be ex-
plored in the future.
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